Skip to main content

News

Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
12/27/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
DownloadPDF format download (opens in new window)
12/03/2021
Marinus Pharmaceuticals Announces New Clinical and Research Data to be Presented at American Epilepsy Society Meeting
DownloadPDF format download (opens in new window)
11/22/2021
Marinus Pharmaceuticals Announces Nine Presentations and Virtual Investor Event at American Epilepsy Society 2021 Annual Meeting
DownloadPDF format download (opens in new window)
11/15/2021
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
DownloadPDF format download (opens in new window)
11/09/2021
Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2021 Financial Results
DownloadPDF format download (opens in new window)
11/08/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
10/26/2021
Marinus Pharmaceuticals to Provide Business Update and Announce Third Quarter 2021 Financial Results on November 9, 2021
DownloadPDF format download (opens in new window)
10/25/2021
Marinus Pharmaceuticals Joins the Loulou Foundation in Collaboration on CANDID, a Comprehensive Observational Study in CDKL5 Deficiency Disorder
DownloadPDF format download (opens in new window)
10/08/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
10/05/2021
Marinus Pharmaceuticals Provides Strategic Update at Virtual R&D Event
DownloadPDF format download (opens in new window)
09/28/2021
Marinus Pharmaceuticals Announces Virtual R&D Event on October 5, 2021
DownloadPDF format download (opens in new window)
09/20/2021
Marinus Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of New Drug Application for Ganaxolone in CDKL5 Deficiency Disorder
DownloadPDF format download (opens in new window)
09/09/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
08/26/2021
European Medicines Agency Grants Marinus Pharmaceuticals Accelerated Assessment of Ganaxolone for Treatment of CDKL5 Deficiency Disorder
DownloadPDF format download (opens in new window)
08/25/2021
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
DownloadPDF format download (opens in new window)
08/17/2021
Marinus Pharmaceuticals Reports Topline Ganaxolone Phase 2 Open-Label Results in Tuberous Sclerosis Complex and Receives FDA Orphan Drug Designation
DownloadPDF format download (opens in new window)
08/10/2021
Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results
DownloadPDF format download (opens in new window)
08/06/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
08/03/2021
Marinus Pharmaceuticals to Provide Business Update and Announce Second Quarter 2021 Financial Results on August 10, 2021
DownloadPDF format download (opens in new window)
08/03/2021
Marinus Pharmaceuticals Announces Exclusive Collaboration with Orion Corporation for European Commercialization of Ganaxolone
DownloadPDF format download (opens in new window)
08/03/2021
Marinus Pharmaceuticals Submits New Drug Application (NDA) to FDA for Ganaxolone for the Treatment of Seizures Associated with CDKL5 Deficiency Disorder and Provides Pipeline Update
DownloadPDF format download (opens in new window)
07/01/2021
Marinus Pharmaceuticals Further Strengthens Board of Directors with Appointment of Santiago Arroyo, M.D., Ph.D.
DownloadPDF format download (opens in new window)
06/22/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
06/14/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
06/11/2021
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
DownloadPDF format download (opens in new window)
05/17/2021
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2021 Financial Results
DownloadPDF format download (opens in new window)
05/13/2021
Marinus Pharmaceuticals Reschedules First Quarter 2021 Financial Results Conference Call
DownloadPDF format download (opens in new window)
05/07/2021
Marinus Pharmaceuticals to Provide Business Update and Announce First Quarter 2021 Financial Results on May 13, 2021
DownloadPDF format download (opens in new window)
04/28/2021
Marinus Pharmaceuticals to Present at Multiple Upcoming Investor Conferences
DownloadPDF format download (opens in new window)
04/12/2021
Marinus Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
04/12/2021
Marinus Pharmaceuticals Bolsters Leadership Team with Two New Appointments
DownloadPDF format download (opens in new window)
03/24/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
03/24/2021
Marinus Pharmaceuticals Appoints Dr. Saraswathy (Sara) Nochur to Board of Directors
DownloadPDF format download (opens in new window)
03/09/2021
Marinus Pharmaceuticals Provides Business Update and Reports Fourth Quarter 2020 Financial Results
DownloadPDF format download (opens in new window)
02/23/2021
Marinus Pharmaceuticals Unveils New Brand as the Company Prepares for Commercialization
DownloadPDF format download (opens in new window)
02/17/2021
Marinus Pharmaceuticals to Participate in Multiple Investor Healthcare and Life Sciences Conferences
DownloadPDF format download (opens in new window)
02/12/2021
Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
DownloadPDF format download (opens in new window)
02/10/2021
Marinus Pharmaceuticals to Provide Business Update and Announce Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021
DownloadPDF format download (opens in new window)
01/26/2021
Marinus Enrolls First Patient in Pivotal Phase 3 Clinical Trial of IV Ganaxolone in Refractory Status Epilepticus
DownloadPDF format download (opens in new window)
01/13/2021
Marinus Pharmaceuticals Receives Positive Response from FDA on Sufficiency of One Phase 3 Clinical Trial for Filing of New Drug Application (NDA) for the Use of Ganaxolone in CDKL5 Deficiency Disorder (CDD)
DownloadPDF format download (opens in new window)
01/06/2021
Marinus Pharmaceuticals to Participate in 39th Annual J.P. Morgan Healthcare Conference and the H.C. Wainwright Bioconnect Conference
DownloadPDF format download (opens in new window)